Exact Sciences Corporation [EXAS] Is Currently 6.71 below its 200 Period Moving Avg: What Does This Mean?

Exact Sciences Corporation [NASDAQ: EXAS] traded at a high on 08/25/22, posting a 6.71 gain after which it closed the day’ session at $39.90. The company report on August 2, 2022 that Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


ADAPT Triad minimal residual disease analysis study intended to evaluate the association between circulating tumor DNA (ctDNA) positivity and recurrence intervals.

Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, announced today that it has entered a collaboration agreement with the West German Study Group (WSG), an international research institution that focuses on practice-changing clinical studies in breast cancer. Together, Exact Sciences and WSG plan to conduct a prospective, multicenter validation study in hormone receptor (HR)-positive, HER2-negative early breast cancer patients. The study is intended to demonstrate the ability of Exact Sciences’ tumor-informed ctDNA liquid biopsy test to detect minimal residual disease (MRD) and to collect important long-term follow-up and outcome data.

The results of the trading session contributed to over 2922586 shares changing hands. Over the past one week, the price volatility of Exact Sciences Corporation stands at 5.43% while the volatility over the past one month is 5.81%.

The market cap for EXAS stock reached $7.38 billion, with 176.36 million shares outstanding and 175.40 million shares in the current float. Compared to the average trading volume of 2.18M shares, EXAS reached a trading volume of 2922586 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Exact Sciences Corporation [EXAS]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EXAS shares is $71.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EXAS stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Credit Suisse have made an estimate for Exact Sciences Corporation shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on August 25, 2022. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Neutral. The new note on the price target was released on June 03, 2022, representing the official price target for Exact Sciences Corporation stock. Previously, the target price had yet another drop from $160 to $130, while Raymond James kept a Outperform rating on EXAS stock. On July 29, 2021, analysts decreased their price target for EXAS shares from 165 to 145.

The Average True Range (ATR) for Exact Sciences Corporation is set at 2.44, with the Price to Sales ratio for EXAS stock in the period of the last 12 months amounting to 3.81. The Price to Book ratio for the last quarter was 2.19, with the Price to Cash per share for the same quarter was set at 3.94.

How has EXAS stock performed recently?

Exact Sciences Corporation [EXAS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.69. With this latest performance, EXAS shares dropped by -13.82% in over the last four-week period, additionally sinking by -47.19% over the last 6 months – not to mention a drop of -60.69% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EXAS stock in for the last two-week period is set at 44.29, with the RSI for the last a single of trading hit 46.19, and the three-weeks RSI is set at 44.20 for Exact Sciences Corporation [EXAS]. The present Moving Average for the last 50 days of trading for this stock 43.29, while it was recorded at 37.20 for the last single week of trading, and 63.17 for the last 200 days.

Exact Sciences Corporation [EXAS]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Exact Sciences Corporation [EXAS] shares currently have an operating margin of -41.27 and a Gross Margin at +68.66. Exact Sciences Corporation’s Net Margin is presently recorded at -33.71.

Return on Equity for this stock declined to -19.18, with Return on Assets sitting at -9.56.

Exact Sciences Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.50.

Insider trade positions for Exact Sciences Corporation [EXAS]

There are presently around $6,470 million, or 91.40% of EXAS stock, in the hands of institutional investors. The top three institutional holders of EXAS stocks are: VANGUARD GROUP INC with ownership of 15,977,871, which is approximately 2.147% of the company’s market cap and around 0.90% of the total institutional ownership; PRICE T ROWE ASSOCIATES INC /MD/, holding 15,422,384 shares of the stock with an approximate value of $615.35 million in EXAS stocks shares; and ARK INVESTMENT MANAGEMENT LLC, currently with $597.37 million in EXAS stock with ownership of nearly 4.523% of the company’s market capitalization.

Positions in Exact Sciences Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 231 institutional holders increased their position in Exact Sciences Corporation [NASDAQ:EXAS] by around 10,509,199 shares. Additionally, 272 investors decreased positions by around 15,152,564 shares, while 102 investors held positions by with 136,504,914 shares. The mentioned changes placed institutional holdings at 162,166,677 shares, according to the latest SEC report filing. EXAS stock had 51 new institutional investments in for a total of 1,287,629 shares, while 99 institutional investors sold positions of 2,504,682 shares during the same period.


Please enter your comment!
Please enter your name here